Tesamorelin (30 Day)

Explore Tesamorelin through appropriate clinical monitoring.

Approved-use context: Branded Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It affects growth-hormone signaling and can reduce visceral abdominal fat.

What to expect: Your clinician should establish whether treatment is on-label or off-label. Screening should address active cancer, pregnancy, pituitary disease, glucose intolerance or diabetes, and other medications. Monitoring may include glucose and IGF-1, along with swelling, joint symptoms, and injection reactions.